Why TransMedics Stock Is Skyrocketing Today
Shares of leading organ transplant technology company TransMedics (NASDAQ: TMDX) rose 15% as of noon ET on Thursday, according to data provided by S&P Global Market Intelligence.
TransMedics reported second-quarter earnings that rocketed past analysts' expectations. The company's revenue grew by 38% in Q2, and its earnings per share of $0.92 doubled analysts' anticipation.
These strong results, paired with management raising full-year sales guidance from $575 million at the midpoint to $595 million, sparked a move higher for the stock.
Source Fool.com